MYBPC1 Activators
MYBPC1 Activators centers on their ability to modulate signaling pathways and secondary messengers, primarily cyclic nucleotides like cAMP, which in turn can influence the functional dynamics of sarcomeric proteins, such as MYBPC1. Forskolin, a direct adenylyl cyclase activator, and Rolipram, a PDE4, are examples of chemicals that elevate intracellular cAMP levels. Elevated cAMP activates Protein Kinase A (PKA), which is known to phosphorylate various proteins within the sarcomere. Given that MYBPC1 is a component of the sarcomere, alterations in phosphorylation patterns due to elevated cAMP can influence MYBPC1's binding dynamics, stability, or interactions with other sarcomeric proteins.
On the other hand, calcium modulators, such as A23187, a calcium ionophore, and Ryanodine, a modulator of ryanodine receptors, act by adjusting intracellular calcium concentrations. Calcium is integral to muscle contraction, and changes in its levels directly influence the contractile apparatus, of which MYBPC1 is a part. By modulating calcium dynamics, the role or interactions of MYBPC1 in sarcomere contraction can be indirectly influenced. Adrenergic signaling, evoked by agents like Epinephrine, also converges on the cAMP pathway, affecting the dynamics of sarcomeric proteins. Similarly, various PDE, such as Cilostamide, Milrinone, and Cilostazol, ensure sustained cAMP signaling by its degradation. This continuous signaling might further modulate the functional state or interactions of MYBPC1 within the sarcomere. Lastly, compounds like Blebbistatin, which directly modulate myosin function, can influence the overall sarcomere dynamics. Since MYBPC1's role is closely tied to myosin and sarcomere function, modulating myosin activity can provide an indirect avenue to influence MYBPC1's operational state or interactions. In essence, this class of compounds, while not direct activators of MYBPC1, offers indirect means to modulate the protein by targeting upstream signaling pathways or interacting partners that have bearing on its function or interactions within the muscle sarcomere.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Adenylyl cyclase activator that increases intracellular cAMP levels. Elevated cAMP activates PKA, which can phosphorylate proteins in sarcomeres, where MYBPC1 is located, possibly affecting its binding affinity or function. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $75.00 $212.00 | 18 | |
PDE4 inhibitor preventing cAMP degradation. Sustained cAMP signaling may modulate the phosphorylation status of sarcomeric proteins, possibly including MYBPC1. | ||||||
Dibutyryl-cAMP | 16980-89-5 | sc-201567 sc-201567A sc-201567B sc-201567C | 20 mg 100 mg 500 mg 10 g | $45.00 $130.00 $480.00 $4450.00 | 74 | |
Cell-permeable cAMP analog that activates PKA. PKA phosphorylation in the sarcomere can influence MYBPC1's function or interaction with other sarcomeric proteins. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $54.00 $128.00 $199.00 $311.00 | 23 | |
Calcium ionophore. Since MYBPC1 interacts with myosin, altering intracellular calcium levels can modulate sarcomere contraction dynamics, which may indirectly influence MYBPC1's role in this process. | ||||||
(−)-Epinephrine | 51-43-4 | sc-205674 sc-205674A sc-205674B sc-205674C sc-205674D | 1 g 5 g 10 g 100 g 1 kg | $40.00 $102.00 $197.00 $1739.00 $16325.00 | ||
Acts on adrenergic receptors, increasing cAMP levels. Elevated cAMP can affect sarcomeric protein interactions and dynamics, possibly altering the function or localization of MYBPC1 in the sarcomere. | ||||||
Cilostamide (OPC 3689) | 68550-75-4 | sc-201180 sc-201180A | 5 mg 25 mg | $90.00 $350.00 | 16 | |
PDE3 inhibitor, raising cAMP levels. Elevated cAMP levels may modulate the phosphorylation status of sarcomeric proteins, including potentially MYBPC1. | ||||||
Milrinone | 78415-72-2 | sc-201193 sc-201193A | 10 mg 50 mg | $162.00 $683.00 | 7 | |
Another PDE3 inhibitor. Increased cAMP from this inhibition can modulate sarcomeric protein dynamics, including the potential modulation of MYBPC1. | ||||||
Cilostazol | 73963-72-1 | sc-201182 sc-201182A | 10 mg 50 mg | $107.00 $316.00 | 3 | |
PDE3 inhibitor, elevating cAMP. Elevated cAMP affects the phosphorylation status of sarcomeric proteins, potentially modulating MYBPC1's role or interaction within the sarcomere. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $159.00 $315.00 $598.00 | 34 | |
Non-specific PDE inhibitor elevating both cAMP and cGMP. These secondary messengers may influence sarcomeric protein interactions, potentially including those involving MYBPC1. | ||||||
Ryanodine | 15662-33-6 | sc-201523 sc-201523A | 1 mg 5 mg | $219.00 $765.00 | 19 | |
Modulates ryanodine receptors, altering calcium release from the sarcoplasmic reticulum. Changes in calcium dynamics can influence sarcomere function and may indirectly affect MYBPC1's role within this cellular context. | ||||||